Evolent Health, Inc.

  • Moat Score
  • Safety Score
  • Market Cap $1.20B
  • PE -13
  • Debt $661.99M
  • Cash $178.50M
  • EV $1.68B
  • FCF -$6.13M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$93.45M
EBIT-$40.49M
ROE-9%
ROA-2%
FCF-$6.13M
Equity$1.00B
Growth Stability1
PE-12.81
PB1.2
P/FCF-195.38
P/S0.47
Price/Cash0.15
Debt/Equity0.66
Debt/FCF-108.03
Net Margins-4%
Gross Margins14%
Op. Margins-2%
Sales Growth YoY16%
Sales Growth QoQ4%
Sales CAGR27%
FCF CAGR2%
Equity CAGR-0%
Earnings Growth YoY-26%
Earnings Growth QoQ-2%
Sales CAGR 5Y33%
FCF CAGR 5Y22%
Equity CAGR 5Y14%
Earnings CAGR 3Y43%
Sales CAGR 3Y43%
FCF CAGR 3Y132%
Equity CAGR 3Y19%
Market Cap$1.20B
Revenue$2.55B
Assets$2.54B
Total Debt$661.99M
Cash$178.50M
Shares Outstanding114.68M
EV1.68B
Moat Score10%
Safety Score70%
Working Capital-108.38M
Current Ratio0.85
Gross Profit$367.35M
Shares Growth 3y11%
Equity Growth QoQ-4%
Equity Growth YoY-6%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. The company's reportable segments are Service segment which includes value-based care services, specialty care management services and comprehensive health plan administration services. and True Health segment consists of a commercial health plan it operates in New Mexico that focuses on small and large businesses. It generates a majority of its revenue from the Service segment.

SEC Filings

Direct access to Evolent Health, Inc. (EVH) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Evolent Health, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Evolent Health, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Evolent Health, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Evolent Health, Inc..

= -$69M
012345678910TV
fcf-$6.1M-$6.2M-$6.3M-$6.4M-$6.5M-$6.6M-$6.8M-$6.9M-$7M-$7.1M-$7.2M-$72M
DCF-$5.7M-$5.2M-$4.8M-$4.5M-$4.1M-$3.8M-$3.5M-$3.3M-$3M-$2.8M-$28M
Value-$69M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-89%-16%-9%-44%-36%-4%-1%-7%-4%-4%
ROA--6%-3%-20%-20%-0%0%-3%-2%-2%
ROE-25%-7%-5%-33%-54%-5%-2%-13%-9%-9%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF--2.18-3.67-3.76-6.3415.67-8.275.24-108.03-108.03
Debt over Equity0.130.120.190.320.470.310.480.560.660.66
Growth Stability---------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-71%44%10%35%-2%49%45%30%33%
Earnings YoY growth--69%-22%464%9%-89%-49%642%-34%-
Equity YoY growth-15%14%-22%-33%12%24%24%-6%14%
FCF YoY growth-9%8%30%-42%-130%-463%-328%-105%22%